Jun 15, 2022 / 08:20PM GMT
Nicholas Hallatt - Goldman Sachs Group, Inc., Research Division - Research Analyst
I'm excited to start our next session, where we're joined by Genmab. My name is Nick Hallatt. I work with the European Biopharma team out of London. I'm joined today by Anthony, the CFO; and Judith, the Chief Development Officer.
So perhaps, Anthony, if you'd like to kick off with an introduction to the company, a kind of overview of the technology platform that you developed.
Anthony Pagano - Genmab A/S-Executive VP&CFO
That would be super. Thanks, Nick. And it's great to be here today in person after so many years of doing this virtually. It's really super to be back here. So as you said, Nick, I'll just take a couple of minutes upfront, set a bit of context, and then I would really look forward to getting to your questions.
Nicholas Hallatt - Goldman Sachs Group, Inc., Research Division - Research Analyst
Perfect.
Anthony Pagano - Genmab A<
Genmab A/S at Goldman Sachs Global Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers